Preventive Services for Non-Grandfathered (PPACA) Plans: Immunizations - CAM 109HB

Description
The U.S. Patient Protection and Affordable Care Act (PPACA) was passed by Congress and signed into law by the president in March 2010. The preventive services component of the law became effective Sept. 23, 2010. A component of the law was a requirement that all “non-grandfathered” health insurance plans are required to cover those preventive medicine services given an “A” or “B” recommendation by the U.S. Preventive Services Task Force (USPSTF).

Plans are not required to provide coverage for the preventive services if they are delivered by out-of-network providers.

Task force recommendations are graded on a five-point scale (A – E), reflecting the strength of evidence in support of the intervention. Grade A: There is good evidence to support the recommendation that the condition be specifically considered in a periodic health examination. Grade B: There is fair evidence to support the recommendation that the condition be specifically considered in a periodic health examination. Grade C: There is insufficient evidence to recommend for or against the inclusion of the condition in a periodic health examination, but recommendations may be made on other grounds. Grade D: There is fair evidence to support the recommendation that the condition be excluded from consideration in a periodic health examination. Grade E: There is good evidence to support the recommendation that the condition be excluded from consideration in a periodic health examination.

Those preventive medicine services listed as Grade A & B recommendations are covered without cost sharing (i.e., deductible, coinsurance or copay) by Health Plans for appropriate preventive care services provided by an in-network provider. If the primary purpose for the office visit is for other than Grade A or B USPSTF preventive care services, deductible, coinsurance or copay may be applied.

Services are typically included as part of a normal wellness visit; the appropriate office visit code should be used. Evaluation and Management codes for preventive services 99381 – 99397 will always be considered preventive. CPT Codes 99401 – 99404, when used to designate a preventive service, must have the applicable wellness/preventive diagnosis code as the primary reason for the visit.

When the primary purpose of the service is the delivery of an evidence-based service in accordance with a U.S. Preventive Services Task Force A or B rating in effect and other preventive services identified in preventive services mandates (legislative or regulatory), the service may be billed with Modifier ‘-33.'

TRAVEL IMMUNIZATIONS ADDITIONAL INFORMATION:

Immunizations that are specific to travel (e.g., typhoid, yellow fever, cholera, plague and Japanese encephalitis virus) are not required by PPACA and are excluded from coverage.  

NOTE: THIS POLICY APPLIES ONLY TO NON-GRANDFATHERED PLANS.  

Background
The ACIP develops recommendations on how to use vaccines to control disease in the United States. The recommendations include the age(s) when the vaccines should be given, the number of doses needed, the amount of time between doses and precautions and contraindications.

Professional organizations that work with the ACIP to develop the annual childhood and adult schedules include the American Academy of Pediatrics (AAP), the American Academy of Family Physicians (AAFP), the American College of Obstetricians and Gynecologists (ACOG) and the American College of Physicians (ACP).

The Committee's recommendations are forwarded to CDC’s director for approval. Once the ACIP recommendations have been reviewed and approved by the CDC director and the U.S. Department of Health and Human Services, they are published in CDC’s Morbidity and Mortality Weekly Report (MMWR). The MMWR publication represents the final and official CDC recommendations for immunization of the U.S. population.

Each year, the Advisory Committee on Immunization Practices (ACIP) publishes immunization schedules for persons age birth through 18 years. These schedules summarize recommendations for routine vaccines for children age 18 years and younger.

The recommended immunization schedules for persons age birth through 18 years and the catch-up immunization schedule have been approved by the Advisory Committee on Immunization Practices (ACIP), the American Academy of Pediatrics, the American Academy of Family Physicians and the American College of Obstetricians and Gynecologists. 

Policy
The following immunizations are considered MEDICALLY NECESSARY when given in accordance with ACIP guidelines:

An immunization is considered NOT MEDICALLY NECESSARY if it does not meet Vaccine Policy requirements for FDA labeling (including age and/or gender limitations) and if it does not have definitive ACIP recommendations published in the CDC’s Morbidity and Mortality Weekly Report (MMWR).

Age Group column: This column is provided for informational use only. For purposes of this document: Adult means age 18 years and up; pediatric means age 0 – 18 years.

Benefit Limits column: Benefit Limits in bold text are from FDA labeling and ACIP recommendations. Codes that indicate “For applicable age, see code description” are limited to the age(s) listed in the code description.

PREVENTIVE IMMUNIZATIONS

These codes do not have a diagnosis code requirement for preventive benefits to apply. 

PREVENTIVE IMMUNIZATIONS

These codes do not have a diagnosis code requirement for preventive benefits to apply.

 
Category: Code(s): Description: Age Group: Benefit Limits: Age/Other  

Immunization administration

Preventive when included as part of a preventive immunization.

90460 Immunization administration through 18 years of age via any route of administration, with counseling by physician or other qualified health care professional; first or only component of each vaccine or toxoid administered Pediatric For applicable age see code description  
90461 Immunization administration through 18 years of age via any route of administration, with counseling by physician or other qualified health care professional; each additional vaccine or toxoid component administered (List separately in addition to code for primary procedure) Pediatric For applicable age see code description  
90471 Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); one vaccine (single or combination vaccine/toxoid) Both  
90472 Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); each additional vaccine (single or combination vaccine/toxoid) (List separately in addition to code for primary procedure) Both  
90473 Immunization administration by intranasal or oral route; one vaccine (single or combination vaccine/toxoid) Both  
90474 Immunization administration by intranasal or oral route; each additional vaccine (single or combination vaccine/toxoid) (List separately in addition to code for primary procedure) Both  
G0008 Administration of influenza virus vaccine Both  
G0009 Administration of pneumococcal vaccine Both  
G0010 Administration of hepatitis B vaccine Both  
Meningococcal 90619 Meningococcal conjugate vaccine, serogroups A, C, W, Y, quadrivalent, tetanus toxoid carrier (MenACWY-TT), for intramuscular use Both

-

 
90620  Meningococcal recombinant protein and outer membrane vesicle vaccine, serogroup B (MenB-4C), 2 dose schedule, for intramuscular use  Both 

Benefit Limit:

Age 10 and up

 
90621 Meningococcal recombinant lipoprotein vaccine, serogroup B (MenB-FHbp), 2 or 3 dose schedule, for intramuscular use Both

Benefit Limit:

Age 10 and up

 
90623 (effective 10/20/2023) Meningococcal pentavalent vaccine, conjugated Men A, C, W, Y- tetanus toxoid carrier, and Men B-FHbp, for intramuscular use Allowed for 10-25 years old. Allowed only for members between 10-25 years of age  
90644 Meningococcal conjugate vaccine, serogroups C & Y and Haemophilus influenzae b vaccine (Hib-MenCY), 4 dose schedule, when administered to children 2 – 15 months of age, for intramuscular use Pediatric For applicable age see code description.  
90733 Meningococcal polysaccharide vaccine , serogroups A, C, Y, W-135, quadrivalent (MPSV4) for subcutaneous use Both    
90734 Meningococcal conjugate vaccine, serogroups A, C, Y and W-135, quadrivalent (MenACWY), for intramuscular use Both    
Hepatitis A 90632 Hepatitis A vaccine (HepA), adult dosage, for intramuscular use Adult For applicable age see code description.  
90633 Hepatitis A vaccine (HepA), pediatric/ adolescent dosage-2 dose schedule, for intramuscular use Pediatric For applicable age see code description.  
90634 Hepatitis A vaccine (HepA), pediatric/adolescent dosage-3 dose schedule, for intramuscular use Pediatric For applicable age see code description.  
90636 Hepatitis A and hepatitis B vaccine (HepA-HepB), adult dosage, for intramuscular use Adult For applicable age see code description.  
Haemophilus influenza b (Hib): 90645 Hemophilus influenza b vaccine (Hib), HbOC conjugate (4 dose schedule), for intramuscular use Both -  
90646 Hemophilus influenza b vaccine (Hib), PRP-D conjugate, for booster use only, intramuscular use Both -  
90647 Haemophilus influenzae b vaccine (Hib), PRP-OMP conjugate, 3 dose schedule, for intramuscular use Both -  
90648 Haemophilus influenzae b vaccine (Hib), PRP-T conjugate, 4 dose schedule, for intramuscular use Both -  
Human papillomavirus (HPV) 90649

Human Papilloma virus vaccine, types 6, 11, 16, 18, quadrivalent (HPV4), 3 dose schedule, for intramuscular use

Both Benefit Limit: Ages 9 – 26yrs. Ends on 27th birthday.  
90650 Human Papilloma virus vaccine, types 16, 18, bivalent (HPV2), 3 dose schedule, for intramuscular use Both

Benefit Limit: Females, ages 9 – 26 yrs. Ends on 27th birthday. This vaccine is not covered for males.

 
90651 Human Papillomavirus vaccine types 6, 11, 16, 18, 31, 33, 45, 52, 58, nonavalent (9vHPV), 2 or 3 dose schedule, for intramuscular use Both Benefit Limit: Ages 9 – 26yrs. Ends on 27th birthday.COV  
COVID

0121A

Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Age 6 months and above    
0141A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Age 6 months and above    
0142A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Age 6 months and above    
0151A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Age 6 months and above    
0171A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; first dose Age 6 months and above    
0172A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; first dose Age 6 months and above    
0124A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Age 6 months and above    
0134A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Age 6 months and above    
0144A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Age 6 months and above    
0154A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Age 6 months and above    
0164A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Age 6 months and above    
0173A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Age 6 months and above    
0174A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Age 6 months and above    
  90480 (effective 09/11/2023) Immunization administration by intramuscular injection of severe acute respiratory syndrom cornavirus 2 (SARS-CO V-2) (coronavirus disease (COVID-19) vaccine, single dose All ages    
  91300 (terminated as of 04/18/2023) Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease(COVID-19)) vaccine, mRNA, LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted, for intramuscular use. 6 years of age and greater    
  91301 (terminated as of 04/18/2023) Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease (COVID-19)) vaccine, mRNA, LNP, spike protein, preservative free, 100 mcg/0.5 mL dosage, for intramuscular use 6 years of age and greater    
  91302 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease (COVID-19)) vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOx1) vector, preservative free, 5x1010 viral particles/0.5mL dosage, for intramuscular use Age 6 months and above    
  91303 (terminated as of 06/01/2023) Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease (COVID-19)) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x1010 viral particles/0.5mL dosage, for intramuscular use 6 years of age and greater    
  91304 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease (COVID-19)) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5mL dosage, for intramuscular use. Age 6 months and above    
  91305 (terminated as of 04/18/2023) Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease (COVID-19)) vaccine, mRNA, LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use 6 years of age and greater    
  91306 (terminated on 04/18/2023) Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease (COVID-19)) vaccine, mRNA, LNP, spike protein, preservative free, 50 mcg/0.25 mL dosage, for intramuscular use 6 years of age and greater    
  91307 (terminated as of 04/18/2023) Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease (COVID-19)) vaccine, mRNA, LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use 6 years of age and greater    
  91308 (terminated as of 04/18/2023) Severe acute respiratory syndrome coronavirus 2 (SARS-CoV -2) (coronavirus disease (COVID -19)) vaccine, mRNA-LNP, spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use 6 years of age and greater    
  91309 (terminated as of 04/18/2023) Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease (COVID-19)) vaccine, mRNA, LNP, spike protein, preservative free, 50 mcg/0.5 mL dosage, for intramuscular use 6 years of age and greater    
  91311 (terminated as of 04/18/2023) Severe acute respiratory syndrome coronavirus 2 (SARS-CoV -2) (coronavirus disease (COVID -19)) vaccine, mRNA-LNP, spike protein, preservative free, 25 mcg/0.25 mL dosage, for intramuscular use 6 years of age and greater    
  91312 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease (COVID-19)) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use Age 6 months and above    
  91313 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease (COVID-19)) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 50 mcg/0.5 mL dosage, for intramuscular use Age 6 months and above    
  91314 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease (COVID-19)) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 25 mcg/0.25 mL dosage, for intramuscular use Age 6 months and above    
  91315 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use Age 6 months and above    
  91316 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease (COVID-19)) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 25 mcg/0.25 mL10 mcg/0.2 mL dosage, for intramuscular use Age 6 months and above    
  91317 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease (COVID-19)) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use Age 6 months and above    
  91318 (effective 09/11/2023) Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 3 mcg/0.23 mL dosage, tris-sucrose formulation, for intramuscular use 6 months- 4 years    
  91319 (effective 09/11/2023) Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease (COVID-19)) vaccine, mRNA-LNP, spike protein, 10 mcg/0.23 mL dosage, tris-sucrose formulation, for intramuscular use 5 years through 11 years    
  91320 (effective 09/11/2023) Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease (COVID-19)) vaccine, mRNA-LNP, spike protein, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use 12 years and older    
  91321 (effective 09/11/2023) Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease (COVID-19)) vaccine, mRNA-LNP, 25 mcg/0.25 mL dosage, for intramuscular use 6 months through 11 years    
  91322 (effective 09/11/2023) Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease (COVID-19)) vaccine, mRNA-LNP, 50 mcg/0.5 mL dosage, for intramuscular us 12 years and older    
Respiratory Syncytial Virus 90679 (effective 05/05/2023) Respiratory syncytial virus vaccine, preF, recombinant, subunit, adjuvanted, for intramuscular use Age 60 years and older    
  90380 (effective 07/17/2023) Respiratory syncytial virus, monoclonal antibody, seasonal dose; 0.5 mL dosage, for intramuscular use. Neonate-24 months of age (effective 07/17/2023)    
  90381 (effective 07/17/023) Respiratory syncytial virus, monoclonal antibody, seasonal dose; 1mL dosage, for intramuscular use. Neonate-24 months of age (effective 07/17/2023)    

Seasonal Influenza (‘flu’)

Note: Additional new seasonal flu immunization codes that are recently FDA-approved, but are not listed here, may be eligible for preventive benefits as of the FDA approval date.

90630 Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, for intradermal use Both -  
90653 Influenza vaccine, inactivated (IIV), subunit, adjuvanted, for intramuscular use Both -  
90654 Influenza virus vaccine, trivalent (IIV3), split virus, preservative-free, for intradermal use Adult Benefit Limit: 18 years – 64 years. Ends on 65th birthday.  
90655 Influenza virus vaccine, trivalent (IIV3), split virus, preservative free, when administered to children 6 – 35 months of age, for intramuscular use Pediatric For applicable age see code description.  
90655 (effective 1/1/2017)  Influenza virus vaccine, trivalent (IIV3), split virus, preservative free, 0.25 mL dosage, for intramuscular use  both    
90656 Influenza virus vaccine, trivalent (IIV3), split virus, preservative free, when administered to individuals 3 years and older, for intramuscular use Both For applicable age see code description.  
90656 (effective 1/1/2017)  Influenza virus vaccine, trivalent (IIV3), split virus, preservative free, 0.5 mL dosage, for intramuscular use  Both     
90657 Influenza virus vaccine, trivalent(IIV3), split virus, when administered to children 6 – 35 months of age, for intramuscular use Pediatric For applicable age see code description.  
90657 (effective 1/1/2017)  Influenza virus vaccine, trivalent(IIV3), split virus, 0.25 mL dosage, for intramuscular use  both    
90658 Influenza virus vaccine, trivalent (IIV3), split virus, when administered to individuals 3 years of age and older, for intramuscular use Both For applicable age see code description.  
90658 (effective 1/1/2017)  Influenza virus vaccine, trivalent (IIV3), split virus, 0.5 mL dosage, for intramuscular use  Both     
90660 Influenza virus vaccine, trivalent, live (LAIV3), for intranasal use Both Benefit Limit: Ages 2 – 49 Years. Ends on 50th birthday  
90661 Influenza virus vaccine (ccIIV3), derived from cell cultures, subunit, preservative and antibiotic free, for intramuscular use Adult

Benefit Limit: Ages 18 years and up

 
90661 (effective 1/1/2017)  Influenza virus vaccine trivalent (ccIIV3), derived from cell cultures, subunit, preservative and antibiotic free, 0.5 mL dosage, for intramuscular use  Adult 

 

 
90662 Influenza virus vaccine (IIV), split virus, preservative free, enhanced immunogenicity via increased antigen content, for intramuscular use Adult

Benefit Limit: Ages 65 years and up

 
90664 Influenza virus vaccine, live (LAIV), pandemic formulation, for intranasal use Both Benefit Limit: Ages 2 – 49 Years. Ends on 50th birthday.  
90666 Influenza virus vaccine (IIV), pandemic formulation, split virus, preservative free, for intramuscular use  Both -  
90667 Influenza virus vaccine (IIV), pandemic formulation, split virus, adjuvanted, for intramuscular use Both -  
90668 Influenza virus vaccine (IIV), pandemic formulation, split virus, for intramuscular use Both -  
90672 Influenza virus vaccine, quadrivalent, live (LAIV4), for intranasal use Both Benefit Limit: Ages 2 – 49 Years. Ends on 50th birthday.  
90673 Influenza virus vaccine, trivalent (RIV3), derived from recombinant DNA (RIV3), hemagglutinin (HA) protein only, preservative and antibiotic free, for intramuscular use  Adult Benefit Limit: Ages 18 – 49 Years. Ends on 50th birthday.  
90674 (effective 1/1/2017)  Influenza virus vaccine, quadrivalent (ccIIV4), derived from cell cultures, subnit, preservative and antibiotic free, 0.5 mL dosage, for intramuscular use   Adult     
90685 Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, when administered to children 6 – 35 months of age, for intramuscular use  Pediatric For applicable age see code description.  
90682 (effective 1/01/2018)  Influenza virus vaccine, quadrivalent (RIV4), derived from recombinant DNA, hemagglutinin (HA) protein only, preservative and antibiotic free, for intramuscular use  Both    
90685 (effective 1/1/2017)  Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.25 mL dosage, for intramuscular use  Both    
90686 Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, when administered to individuals 3 years of age and older, for intramuscular use  Both For applicable age see code description.  
90686 (effective 1/1/2017)  Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use  Both     
90687 Influenza virus vaccine, quadrivalent (IIV4), split virus, when administered to children 6 – 35 months of age, for intramuscular use  Pediatric For applicable age see code description.  
90687 (effective 1/1/2017)  Influenza virus vaccine, quadrivalent (IIV4), split virus, 0.25 mL dosage, for intramuscular use  Both    
90688 Influenza virus vaccine, quadrivalent (IIV4), split virus, when administered to individuals 3 years of age and older, for intramuscular use Both For applicable age see code description.  
90688 (effective 1/1/2017)  Influenza virus vaccine, quadrivalent (IIV4), split virus, 0.5 mL dosage, for intramuscular use  Both     
90689 (effective 01/01/2019) 

Influenza virus vaccine, quadrivalent (IIV4), inactivated, adjuvanted, preservative free, 0.25 mL dosage, for intramuscular use 

Both     
90694 

INFLUENZA VIRUS VACCINE, QUADRIVALENT (AIIV4), INACTIVATED, ADJUVANTED, PRESERVATIVE FREE, 0.5 ML DOSAGE, FOR INTRAMUSCULAR USE 

Both     
90756 (effective 1/1/2018) 

Influenza virus vaccine, quadrivalent (ccIIV4), derived from cell cultures, subunit, antibiotic free, 0.5mL dosage, for intramuscular use TOS Code: V  

Adult     
Q2034 Influenza virus vaccine, split virus, for intramuscular use (Agriflu)  Adult

Benefit Limit: Ages 18 years and up

 
Q2035 Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (AFLURIA)  Both For applicable age see code description.  
Q2036 Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (FLULAVAL)  Both For applicable age see code description.  
Q2037 Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (FLUVIRIN)  Both For applicable age see code description.  
Q2038 Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (Fluzone)  Both For applicable age see code description.  
Q2039 Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (not otherwise specified)  Both For applicable age see code description.  
Pneumococcal polysaccharide (PPSV23)  90732  Pneumococcal polysaccharide vaccine, 23-valent (PPSV23), adult or immunosuppressed patient dosage, when administered to individuals 2 years or older, for subcutaneous or intramuscular use Both  For applicable age see code description.   
Pneumococcal conjugate  90669  Pneumococcal conjugate vaccine, 7 valent (PCV7), for intramuscular use  Pediatric   Benefit Limit: Age 0 – 5 yrs. Ends on 6th birthday   
  90670  Pneumococcal conjugate vaccine, 13 valent (PCV13), for intramuscular use Both   -  
  90671 (effective 12/06/2021)  Pneumococcal conjugate vaccine, 15 valent (PCV15), for intramuscular use  Both     
  90677 (effective 12/15/2021)  Pneumococcal conjugate vaccine, 20 valent (PCV20), for intramuscular use  Both     
  90684 (effective 06/17/2024) Pneumococcal conjugate vaccine, 21 valent (PCV), for intramuscular use Adults    
  S0195   Pneumococcal conjugate vaccine, polyvalent, intramuscular, for children from five years to nine years of age who have not previously received the vaccine Pediatric    For applicable age see code description.   
Respiratory Syncytial Virus 96380 (effective 10/06/2023) Administration of respiratory syncytial virus, monoclonal antibody, seasonal dose by intramuscular injection, with counseling by physician or other qualified health care professional 24 months of age and younger    
  96381 (effective 10/06/2023) Administration of respiratory syncytial virus, monoclonal antibody, seasonal dose by intramuscular injection 24 months of age and younger    
  90683 (effective 5/31/2024) Respiratory syncytial virus vaccine, mRNA Lipid nanoparticles, for intramuscular use. Adults, 60 years of age and greater    
  90678 Respiratory syncytial virus vaccine, preF, subunit, bivalent, for intramuscular use. Adults

Benefit limits should indicate one dose for adults 60 years of age and older

Allowed for pregnant persons between 32 – 36 weeks of gestation (effective 10/11/2023)

 
  90679 Respiratory syncytial virus vaccine, preF, recombinant, subunit, adjuvanted, for intramuscular use. Adults  Benefit limits should indicate one dose for adults 60 years of age and older  
Rotavirus  90680 

Rotavirus vaccine, pentavalent (RV5), 3 dose schedule, live, for oral use 

Pediatric 

Do not begin series in infants older than age 14 wks 6 days.

  • Intervals between doses may be as short as 4wks.
  • If prior vaccination included use of different or unknown brand(s), a total of 3 doses should be given.
 
  90681

Rotavirus vaccine, human, attenuated (RV1), 2 dose schedule, live, for oral use 

Pediatric

Do not begin series in infants older than age 14wks 6 days.

  • Intervals between doses may be as short as 4wks.
  • If prior vaccination included use of different or unknown brand(s), a total of 3 doses should be given.
 
Diphtheria, tetanus toxoids, acellular pertussis and polio inactive (DTap-IPV)  90696  Diphtheria, tetanus toxoids, acellular pertussis vaccine and inactivated poliovirus vaccine (DTaP-IPV), when administered to children 4 through 6 years of age, for intramuscular use  Pediatric  For applicable age see code description.   
  90697  Diphtheria and tetanus toxoids and acellular pertussis vaccine, inactivated poliovirus vaccine, Haemophilus influenzae b PRP-OMP conjugate vaccine, and hepatitis B vaccine (DTaP-IPV-Hib-HepB), for intramuscular use Pediatric  Age 6 weeks – fifth birthday   
Diphtheria, tetanus toxoids, acellular pertussis, haemophilus influenza B, and polio inactive (DTap-IPV/Hib)  90698  Diphtheria, tetanus toxoids, acellular pertussis vaccine, haemophilus influenzae Type b, and inactivated poliovirus vaccine (DTaP-IPV/Hib), for intramuscular use  Both   
Diphtheria, tetanus, acellular pertussis (DTap)  90700  Diphtheria, tetanus toxoids, and acellular pertussis vaccine (DTaP), when administered to individuals younger than 7 years, for intramuscular use  Pediatric  For applicable age see code description   
Diphtheria and tetanus (DT) 90702  Diphtheria and tetanus toxoids adsorbed (DT) when administered to individuals younger than 7 years, for intramuscular use  Pediatric  For applicable age see code description    

Tentanus

 
90703  Tetanus toxoid adsorbed, for intramuscular use  Both   
Measles, Mumps, Rubella (MMR) combination or individual       90704  Mumps virus vaccine, live, for subcutaneous use  Both    
90705 Measles virus vaccine, live, for subcutaneous use  Both    
90706 Rubella virus vaccine, live, for subcutaneous use  Both    
90707 Measles, mumps and rubella virus vaccine (MMR), live, for subcutaneous use  Both    
90708 Measles and rubella virus vaccine, live, for subcutaneous use  Both    
90710 Measles, mumps, rubella, and varicella vaccine (MMRV), live, for subcutaneous use  Both    

Polio (IPV) 

90713  Poliovirus vaccine, inactivated (IPV), for subcutaneous or intramuscular use  Both      
Tetanus and diphtheria (Td)  90714  Tetanus and diphtheria toxoids adsorbed (Td), preservative free, when administered to individuals 7 years or older, for intramuscular use  Both  For applicable age see code description.   
Tetanus, diphtheria toxoids and acellular pertussis (Tdap)  90715  Tetanus, diphtheria toxoids and acellular pertussis vaccine (Tdap), when administered to individuals 7 years or older, for intramuscular use  Both  For applicable age see code description.    

Varicella (VAR) (‘chicken pox’) 

90716 

Varicella virus vaccine (VAR), live, for subcutaneous use  Both    
Diphtheria  90719  Diphtheria toxoid, for intramuscular use  Both     
Diptheria, tetanus and whole pertussis and Haemophilus influenza B (DTwP-Hib)  90720  Diphtheria, tetanus toxoids, and whole cell pertussis vaccine and Haemophilus influenzae b vaccine (DTwP-Hib), for intramuscular use  Both      
Diptheria, tetanus and acellular pertussis and Haemophilus influenza B (DTaP-Hib)  90721  Diphtheria, tetanus toxoids, and acellular pertussis vaccine and Haemophilus influenza b vaccine (DTaP/Hib), for intramuscular use  Both       
Diptheria, tetanus and acellular pertussis, hep B, and polio inactive (DTaP-HepB-IPV)  90723  Diphtheria, tetanus toxoids, acellular pertussis vaccine, hepatitis B, and inactivated poliovirus vaccine (DTaP-HepB-IPV), for intramuscular use  Both  Benefit Limit:  Ages 0 – 6yrs. Ends on 7th birthday.   
Zoster / Shingles (HZV)  90736  Zoster (shingles) vaccine (HZV), live, for subcutaneous injection  Adult  Benefit Limit: Age 50 years and up.   
  90750 (effective 01/01/2017) ZOSTER (SHINGLES) VACCINE (HZV), RECOMBINANT, SUB-UNIT, ADJUVANTED, FOR INTRAMUSCULAR INJECTION  Both Age limit 19 years and if immunodeficiency or immunosuppression exist 19-49 years. Allow for age 50 and greater.  
Hepatitis B
          
90739 Hepatitis B vaccine, adult dosage (2 dose schedule), for intramuscular use Adult For applicable age see code description.  
90740  Hepatitis B vaccine (HepB), dialysis or immunosuppressed patient dosage, 3 dose schedule, for intramuscular use  Both    
90743  Hepatitis B vaccine (HepB), adolescent, 2 dose schedule, for intramuscular use  Pediatric (adolescent only)  For applicable age see code description.   
90744  Hepatitis B vaccine (HepB), pediatric/adolescent dosage, 3 dose schedule, for intramuscular use  Pediatric  For applicable age see code description.   
90746  Hepatitis B vaccine (HepB), adult dosage, 3 dose schedule, for intramuscular use  Adult  For applicable age see code description.    
90747  Hepatitis B vaccine (HepB), dialysis or immunosuppressed patient dosage, 4 dose schedule, for intramuscular use  Both     
90748  Hepatitis B and Haemophilus influenza b vaccine (Hib-HepB), for intramuscular use  Both      
90759 Hepatitis B vaccine (Recombinant) Injectable Suspension, for intramuscular use  Both -  

Procedure and diagnosis codes on Medical Policy documents are included only as a general reference tool for each policy. They may not be all-inclusive.

References

  1. http://www.cdc.gov/vaccines/acip/recs/index.html 
  2. http://www.cdc.gov/vaccines/hcp/acip-recs/index.html 
  3. http://www.cdc.gov/vaccines/schedules/hcp/index.html 
  4. http://www.cdc.gov/vaccines/schedules/downloads/child/0-18yrs-child-combined-schedule.pdf 
  5. http://www.cdc.gov/vaccines/schedules/hcp/imz/child-adolescent.html 
  6. http://www2a.cdc.gov/vaccines/iis/iisstandards/vaccines.asp?rpt=cpt
  7. http://www.cdc.gov/flu/protect/vaccine/vaccines.htm

This medical policy was developed through consideration of peer-reviewed medical literature generally recognized by the relevant medical community, U.S. FDA approval status, nationally accepted standards of medical practice and accepted standards of medical practice in this community, Blue Cross Blue Shield Association technology assessment program (TEC) and other nonaffiliated technology evaluation centers, reference to federal regulations, other plan medical policies, and accredited national guidelines.

"Current Procedural Terminology © American Medical Association. All Rights Reserved"  

History From 2024 Forward     

10/15/2024 Annual review, no change to policy intent. 
08/13/2024 Interim review, adding CPT 90759 to coding section for Hepatitis B. 
06/26/2024 Interim review, adding 90684 (effective 6/17/2024) to the coding section for pneumococcal conjugate vaccine. 
06/05/2024 Interim review, adding 90683 (effective 05312024) to the coding section for respiratory syncytial virus vaccine. 

01/01/2024

NEW POLICY

Complementary Content
${loading}